BBOT Prioritizes KRAS-Mutant Cancer Combinations After Strong BBO-8520 Data
Event summary
- BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L+ KRASG12C inhibitor-experienced NSCLC patients.
- BBO-8520 monotherapy showed a 63% ORR in 2L+ KRASG12C inhibitor-naïve NSCLC with a 100% disease control rate and no grade 3 liver enzyme elevations.
- BBOT is focusing on BBO-8520 combinations in NSCLC and BBO-11818/BBO-1023 combinations in KRAS-mutant cancers.
- $344.1 million in cash as of June 30, 2026, provides runway into 2028.
The big picture
BBOT's strategic focus on combination therapies for KRAS-mutant cancers comes as the field sees growing interest in targeted treatments for these hard-to-treat malignancies. The strong ORR data for BBO-8520 positions the company to compete in a space dominated by established players, but execution risks remain high. The financial runway into 2028 provides breathing room, but investors will be watching for catalysts that could accelerate or derail the development timeline.
What we're watching
- Combination Therapy Efficacy
- How the BBO-8520 plus pembrolizumab combination will perform in larger datasets and whether it can secure regulatory approval.
- Development Timeline
- The pace at which BBOT can advance BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers through clinical trials.
- Financial Runway
- Whether BBOT's $344.1 million cash position will be sufficient to fund operations into 2028 as projected.
Related topics